About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 12 results:

Case report

HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy

Stefania Paolucci, Marta Premoli, Serena Ludovisi, Mario U Mondelli, Fausto Baldanti

Antiviral Therapy 2017; 22:365-368


Case report

Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring

Francesco R Simonetti, Dario Cattaneo, Nadia Zanchetta, Vania Giacomet, Valeria Micheli, Nadia Ciminera, Cristina Gervasoni

Antiviral Therapy 2017; 22:361-363


Case report

Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?

Julien Lupo, Ophélie Dos Santos, Raphaele Germi, Monique Baccard-Longère, Jean-Paul Stahl, Olivier Epaulard, Patrice Morand

Antiviral Therapy 2017; 22:357-359


Short communication

Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni

Antiviral Therapy 2017; 22:353-356


Original article

Activity of ergoferon against lethal influenza A (H3N2) virus infection in mice

Maria A Skarnovich, Alexandra G Emelyanova, Nataliia V Petrova, Alena A Borshcheva, Evgeniy A Gorbunov, Oleg Yu Mazurkov, Maksim O Skarnovich, Sergey A Tarasov, Larisa N Shishkina, Oleg I Epstein

Antiviral Therapy 2017; 22:345-351


Original article

Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects

Martin O Behm, Ka L Yee, Li Fan, Paul Fackler

Antiviral Therapy 2017; 22:337-344


Original article

A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada

Anita C Benoit, Jaime Younger, Kerrigan Beaver, Randy Jackson, Mona Loutfy, Renée Masching, Tony Nobis, Earl Nowgesic, Doe O’Brien-Teengs, Wanda Whitebird, Art Zoccole, Mark Hull, Denise Jaworsky, Anita Rachlis, Sean Rourke, Ann N Burchell, Curtis Cooper, Robert Hogg, Marina B Klein, Nima Machouf, Julio Montaner, Chris Tsoukas, Janet Raboud, Building Bridges, the Canadian Observational Cohort Collaboration

Antiviral Therapy 2017; 22:325-335


Original article

Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects

Yutaka Saisho, Toru Ishibashi, Hidenori Fukuyama, Hiroyuki Fukase, Jingoro Shimada

Antiviral Therapy 2017; 22:313-323


Original article

Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials

Ana Arias, Antonio Aguilera, Vicente Soriano, Laura Benítez-Gutiérrez, Gemma Lledó, Daniel Navarro, Ana Treviño, Esteban Otero, José M Peña, Valentín Cuervas-Mons, Carmen de Mendoza

Antiviral Therapy 2017; 22:307-312


Free
Original article

Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study

Benoît Trottier, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, Brian Wynne, Judy Hopking, Catherine Granier, Michael Aboud

Antiviral Therapy 2017; 22:295-305


Page:
Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.